A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma

Cancer Investigation

Volumn 29, Issue 7, 2011, Pages 451-455

  Hainsworth, John D ^a,b   Infante, Jeffrey R ^a,b   Spigel, David R ^a,b   Arrowsmith, Edward R ^a,c   Boccia, Ralph V ^a,d   Burris, Howard A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Chattanooga Oncology Hematology Associates   (United States)

^d Center for Cancer and Blood Disorders   (United States)

Author keywords

Kidney; Panobinostat HDAC inhibitors

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 2; PANOBINOSTAT; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEHYDRATION; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; WEAKNESS;

AGED; CARCINOMA, RENAL CELL; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 79960197509     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.590568     Document Type: Article

References (19)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowksi RM, Rixe O, Oudard S, Negrier S, Szcylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
2. Escudier B, Eisen T, Stadler WM, Szczylik C,Oudard S, SiebelsM, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
3. Sternberg CN, Davis ID, Mardiak J, Szcylik C, Lee F, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb́a JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J ClinOncol 2010;28:1061-1068.
4. Escudier B, Bellmunt J, Negriers S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-2150.
5. Hudes G, CarducciM, Tomczak P, Dutcher J, Figlin R,KapoorA, Staroslawa E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
6. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Greunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-456.
7. Cameron E, Bachman K, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107. (Pubitemid 29036293)
8. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008;180:1131-1136.
9. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome C-dependent pathway. Cancer Res 1997;57:3697-3707. (Pubitemid 27381212)
10. Itazaku H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y,Matsumoto K, Ishii K, Uotani N, Nakai H. Isolation and structural elucidation of new cyclotetrapeptides, trapoxin A and B, having detransformation activities as antitumor agents. J Antibiotics 1990;12:1524-1532.
11. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115. (Pubitemid 47218059)
12. Kirschbaum M, Zain J, Popplewell L, Pullarkart V, Obadike N, Frankel P, Zweibel J, Forman S, Newman E, Gandara D. Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: a California Cancer Consortium study. J Clin Oncol 2007;25:703s (Abstract #18515).
13. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, AlbitarM, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologicmalignancies. Clin Cancer Res 2006;12:4628-4635. (Pubitemid 44297814)
14. Therasse P, Arbuck SG,EisenhauerAE,Wanders J,KaplanRS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom OT, ChristianMC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-216. (Pubitemid 30099779)
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown SB, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-1947.
17. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931. (Pubitemid 46218695)
18. Stadler WM, Morgohn K, Ferber S, McCulloh W, Thompson JA. A phase II study of depsipeptide in refractorymetastatic renal cell cancer. Clin Genitourinary Cancer 2006;5:57-60.
19. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM. Retinoic acid and the histone deacetylase inhibitor trichostatin: an inhibit the proliferation of human renal cell carcinoma in a xenograft model. Clin Cancer Res 2005;11:3558-3565.